Glial and neuroinflammatory targets for treating substance use disorders.

Bachtell RK, Jones JD, Heinzerling KG, Beardsley PM, Comer SD. (2017) Glial and neuroinflammatory targets for treating substance use disorders. Drug and Alcohol Dependence Nov 1;180:156-170. doi: 10.1016/j.drugalcdep.2017.08.003. Epub 2017 Aug 31.

Behavioral, biological and chemical perspectives on atypical agents targeting the dopamine transporter.

Reith, ME., Blough, BE., Hong, WC., Jones, KT., Schmitt, KC., Baumann, MH., Partilla, JS., Rothman, RB. and Katz, JL. (2015) Behavioral, biological and chemical perspectives on atypical agents targeting the dopamine transporter. Drug and Alcohol Dependence Feb 1;147C:1-19. doi: 10.1016/j.drugalcdep.2014.12.005. Epub 2014 Dec 18

Scientific overview: 2013 BBC plenary symposium on tobacco addiction.

De Biasi, M., McLaughlin, I., Perez, EE., Crooks, PA., Dwoskin, LP., Bardo, MT., Pentel, PR. and Hatsukami, D. (2014) Scientific overview: 2013 BBC plenary symposium on tobacco addiction. Drug and Alcohol Dependence Aug 1;141:107-17. doi: 10.1016/j.drugalcdep.2014.05.013. Epub 2014 Jun 2. Erratum in: Drug Alcohol Depend. 2014 Nov 1;144:290

Behavioral, biological, and chemical perspectives on targeting CRF1 receptor antagonists to treat alcoholism.

Zorrilla, EP., Heilig, M., de Wit, H. and Shaham, Y. (2013) Behavioral, biological, and chemical perspectives on targeting CRF1 receptor antagonists to treat alcoholism. Drug and Alcohol Dependence Mar 1;128(3):175-86. doi: 10.1016/j.drugalcdep.2012.12.017. Epub 2013 Jan 5

Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology: From a symposium on new concepts in mu-opioid pharmacology.

Lamb, K., Tidgewell, K., Simpson, DS., Bohn, LM. and Prisinzano, TE. (2012) Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3):181-8. doi: 10.1016/j.drugalcdep.2011.10.026. Epub 2011 Nov 26

Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: From a symposium on new concepts in mu-opioid pharmacology.

Whistler, JL. (2012) Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3):189-204. doi: 10.1016/j.drugalcdep.2011.10.031. Epub 2012 Jan 9

Functional relevance of μ-δ opioid receptor heteromerization: A Role in novel signaling and implications for the treatment of addiction disorders: From a symposium on new concepts in mu-opioid pharmacology.

Stockton, SD. and Jr, Devi, LA. (2012) Functional relevance of μ-δ opioid receptor heteromerization: A Role in novel signaling and implications for the treatment of addiction disorders: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3):167-72. doi: 10.1016/j.drugalcdep.2011.10.025. Epub 2011 Nov 23

μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: From a symposium on new concepts in mu-opioid pharmacology.

Traynor, J. (2012) μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3):173-80. doi: 10.1016/j.drugalcdep.2011.10.027. Epub 2011 Nov 29